Challenging treatment-resistant major depressive disorder: A roadmap for improved therapeutics

Current Neuropharmacology

Volumn 13, Issue 5, 2015, Pages 616-635

  De Sousa, Rafael T ^a   Zanetti, Marcus V ^a   Brunoni, Andre R ^a   Machado Vieira, Rodrigo ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Antidepressant; Antipsychotic; Diagnosis treatment; Glutamate; Major depressive disorder; Monoamines

Indexed keywords

AGOMELATINE; AMPA RECEPTOR; ARIPIPRAZOLE; BUSPIRONE; CYCLOSERINE; GLUTAMIC ACID; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; KETAMINE; LITHIUM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLANZAPINE; QUETIAPINE; RILUZOLE; RISPERIDONE; S ADENOSYLMETHIONINE; SCOPOLAMINE; THYROID HORMONE; TRAZODONE; TUMOR NECROSIS FACTOR; VENLAFAXINE; ZIPRASIDONE; ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL FEATURE; COGNITIVE THERAPY; DRUG EFFICACY; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; EXERCISE; HUMAN; INFLAMMATION; MAJOR DEPRESSION; META ANALYSIS (TOPIC); PSYCHODYNAMIC PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSCRANIAL DIRECT CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESISTANT DEPRESSION; VAGUS NERVE STIMULATION; ANIMAL; BIBLIOGRAPHIC DATABASE; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; STATISTICS AND NUMERICAL DATA;

ANIMALS; ANTIDEPRESSIVE AGENTS; DATABASES, BIBLIOGRAPHIC; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; HUMANS;

EID: 84946721003     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X13666150630173522     Document Type: Article

References (169)

1. Kessler, R.C.; Berglund, P.; Demler, O.; Jin, R.; Merikangas, K.R.; Walters, E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry, 2005, 62(6), 593-602. http://dx.doi.org/10.1001/archpsyc.62.6.593
2. Greenberg, P.E.; Kessler, R.C.; Birnbaum, H.G.; Leong, S.A.; Lowe, S.W.; Berglund, P.A.; Corey-Lisle, P.K. The economic burden of depression in the United States: how did it change between 1990 and 2000? J. Clin. Psychiatry, 2003, 64(12), 1465-1475. http://dx.doi.org/10.4088/JCP.v64n1211
3. Kessler, R.C.; Akiskal, H.S.; Ames, M.; Birnbaum, H.; Greenberg, P.; Hirschfeld, R.M.; Jin, R.; Merikangas, K.R.; Simon, G.E.; Wang, P.S. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am. J. Psychiatry, 2006, 163(9), 1561-1568. http://dx.doi.org/10.1176/appi.ajp.163.9.1561
4. Trivedi, M.H.; Rush, A.J.; Wisniewski, S.R.; Nierenberg, A.A.; Warden, D.; Ritz, L.; Norquist, G.; Howland, R.H.; Lebowitz, B.; McGrath, P.J.; Shores-Wilson, K.; Biggs, M.M.; Balasubramani, G.K.; Fava, M.; Team, S.D.S. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry, 2006, 163(1), 28-40. http://dx.doi.org/10.1176/appi.ajp.163.1.28
5. McIntyre, R.S.; Filteau, M.J.; Martin, L.; Patry, S.; Carvalho, A.; Cha, D.S.; Barakat, M.; Miguelez, M. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J. Affect. Disord., 2014, 156, 1-7. http://dx.doi.org/10.1016/j.jad.2013.10.043
6. Posternak, M.A.; Zimmerman, M. Switching versus augmentation: a prospective, naturalistic comparison in depressed, treatmentresistant patients. J. Clin. Psychiatry, 2001, 62(2), 135-142; quiz 143. http://dx.doi.org/10.4088/JCP.v62n0212
7. Papakostas, G.I.; Fava, M.; Thase, M.E. Treatment of SSRIresistant depression: a meta-analysis comparing within-versus across-class switches. Biol. Psychiatry, 2008, 63(7), 699-704. http://dx.doi.org/10.1016/j.biopsych.2007.08.010
8. Souery, D.; Serretti, A.; Calati, R.; Oswald, P.; Massat, I.; Konstantinidis, A.; Linotte, S.; Bollen, J.; Demyttenaere, K.; Kasper, S.; Lecrubier, Y.; Montgomery, S.; Zohar, J.; Mendlewicz, J. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J. Clin. Psychopharmacol., 2011, 31(4), 512-516. http://dx.doi.org/10.1097/JCP.0b013e3182228619
9. Souery, D.; Serretti, A.; Calati, R.; Oswald, P.; Massat, I.; Konstantinidis, A.; Linotte, S.; Kasper, S.; Montgomery, S.; Zohar, J.; Mendlewicz, J. Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study. World J. Biol. Psychiatry, 2011, 12(5), 364-375. http://dx.doi.org/10.3109/15622975.2011.590225
10. Poirier, M.F.; Boyer, P. Venlafaxine and paroxetine in treatmentresistant depression. Double-blind, randomised comparison. Br. J. Psychiatry, 1999, 175, 12-16. http://dx.doi.org/10.1192/bjp.175. 1.12
11. Lenox-Smith, A.J.; Jiang, Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int. Clin. Psychopharmacol., 2008, 23(3), 113-119. http://dx.doi.org/10.1097/YIC.0b013e3282f424c2
12. Baldomero, E.B.; Ubago, J.G.; Cercós, C.L.; Ruiloba, J.V.; Calvo, C.G.; López, R.P. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress. Anxiety, 2005, 22(2), 68-76. http://dx.doi.org/10.1002/da.20080
13. Rush, A.J.; Trivedi, M.H.; Wisniewski, S.R.; Stewart, J.W.; Nierenberg, A.A.; Thase, M.E.; Ritz, L.; Biggs, M.M.; Warden, D.; Luther, J.F.; Shores-Wilson, K.; Niederehe, G.; Fava, M.; Team, S.D.S. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med., 2006, 354(12), 1231-1242. http://dx.doi.org/10.1056/NEJMoa052963
14. Bauer, M.; Tharmanathan, P.; Volz, H.P.; Moeller, H.J.; Freemantle, N. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur. Arch. Psychiatry Clin. Neurosci., 2009, 259(3), 172-185. http://dx.doi.org/10.1007/s00406-008-0849-0
15. Thase, M.E.; Entsuah, A.R.; Rudolph, R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry, 2001, 178, 234-241. http://dx.doi.org/10.1192/bjp.178.3.234
16. Nemeroff, C.B.; Entsuah, R.; Benattia, I.; Demitrack, M.; Sloan, D.M.; Thase, M.E. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol. Psychiatry, 2008, 63(4), 424-434. http://dx.doi.org/10.1016/j.biopsych.2007.06.027
17. Schmitt, A.B.; Bauer, M.; Volz, H.P.; Moeller, H.J.; Jiang, Q.; Ninan, P.T.; Loeschmann, P.A. Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity. Eur. Arch. Psychiatry Clin. Neurosci., 2009, 259(6), 329-339. http://dx.doi.org/10.1007/s00406-009-0003-7
18. de Silva, V.A.; Hanwella, R. Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies. Int. Clin. Psychopharmacol., 2012, 27(1), 8-16. http://dx.doi.org/10.1097/YIC.0b013e32834ce13f
19. Fava, M.; Rush, A.J.; Wisniewski, S.R.; Nierenberg, A.A.; Alpert, J.E.; McGrath, P.J.; Thase, M.E.; Warden, D.; Biggs, M.; Luther, J.F.; Niederehe, G.; Ritz, L.; Trivedi, M.H. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am. J. Psychiatry, 2006, 163(7), 1161-1172. http://dx.doi.org/10.1176/ajp.2006.163.7.1161
20. Taylor, D.; Sparshatt, A.; Varma, S.; Olofinjana, O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ, 2014, 348, g1888.
21. Nierenberg, A.A.; Papakostas, G.I.; Petersen, T.; Kelly, K.E.; Iacoviello, B.M.; Worthington, J.J.; Tedlow, J.; Alpert, J.E.; Fava, M. Nortriptyline for treatment-resistant depression. J. Clin. Psychiatry, 2003, 64(1), 35-39. http://dx.doi.org/10.4088/JCP.v64n0108
22. Thase, M.E.; Rush, A.J.; Howland, R.H.; Kornstein, S.G.; Kocsis, J.H.; Gelenberg, A.J.; Schatzberg, A.F.; Koran, L.M.; Keller, M.B.; Russell, J.M.; Hirschfeld, R.M.; LaVange, L.M.; Klein, D.N.; Fawcett, J.; Harrison, W. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch. Gen. Psychiatry, 2002, 59(3), 233-239. http://dx.doi.org/10.1001/archpsyc.59.3.233
23. McGrath, P.J.; Stewart, J.W.; Fava, M.; Trivedi, M.H.; Wisniewski, S.R.; Nierenberg, A.A.; Thase, M.E.; Davis, L.; Biggs, M.M.; Shores-Wilson, K.; Luther, J.F.; Niederehe, G.; Warden, D.; Rush, A.J. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am. J. Psychiatry, 2006, 163(9), 1531-1541; quiz 1666.
24. Nolen, W.A.; van de Putte, J.J.; Dijken, W.A.; Kamp, J.S.; Blansjaar, B.A.; Kramer, H.J.; Haffmans, J. Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta. Psychiatr. Scand., 1988, 78(6), 676-683. http://dx.doi.org/10.1111/j.1600- 0447.1988.tb06403.x
25. Fang, Y.; Yuan, C.; Xu, Y.; Chen, J.; Wu, Z.; Cao, L.; Yi, Z.; Hong, W.; Wang, Y.; Jiang, K.; Cui, X.; Calabrese, J.R.; Gao, K.; Team, O.S. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. J. Clin. Psychopharmacol., 2011, 31(5), 638-642. http://dx.doi.org/10.1097/jcp.0b013e31822bb1d9
26. Seguí, J.; López-Muñoz, F.; Alamo, C.; Camarasa, X.; García- García, P.; Pardo, A. Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study. J. Psychopharmacol., 2010, 24(8), 1201-1207. http://dx.doi.org/10.1177/0269881109102641
27. Carpenter, L.L.; Yasmin, S.; Price, L.H. A double-blind, placebocontrolled study of antidepressant augmentation with mirtazapine. Biol. Psychiatry, 2002, 51(2), 183-188. http://dx.doi.org/10.1016/S0006-3223(01)01262-8
28. Blier, P.; Gobbi, G.; Turcotte, J.E.; de Montigny, C.; Boucher, N.; Hébert, C.; Debonnel, G. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur. Neuropsychopharmacol., 2009, 19(7), 457-465. http://dx.doi.org/10.1016/j.euroneuro.2009.01.015
29. Blier, P.; Ward, H.E.; Tremblay, P.; Laberge, L.; Hébert, C.; Bergeron, R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am. J. Psychiatry, 2010, 167(3), 281-288. http://dx.doi.org/10.1176/appi.ajp.2009.09020186
30. Rocha, F.L.; Fuzikawa, C.; Riera, R.; Hara, C. Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis. J. Clin. Psychopharmacol., 2012, 32(2), 278-281. http://dx.doi.org/10.1097/JCP.0b013e318248581b
31. Rush, A.J.; Trivedi, M.H.; Stewart, J.W.; Nierenberg, A.A.; Fava, M.; Kurian, B.T.; Warden, D.; Morris, D.W.; Luther, J.F.; Husain, M.M.; Cook, I.A.; Shelton, R.C.; Lesser, I.M.; Kornstein, S.G.; Wisniewski, S.R. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a singleblind randomized study. Am. J. Psychiatry, 2011, 168(7), 689-701. http://dx.doi.org/10.1176/appi.ajp.2011.10111645
32. Nelson, J.C.; Papakostas, G.I. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am. J. Psychiatry, 2009, 166(9), 980-991. http://dx.doi.org/10.1176/appi.ajp.2009.09030312
33. Spielmans, G.I.; Berman, M.I.; Linardatos, E.; Rosenlicht, N.Z.; Perry, A.; Tsai, A.C. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med., 2013, 10(3), e1001403. http://dx.doi.org/10.1371/journal.pmed.1001403
34. Shelton, R.C.; Tollefson, G.D.; Tohen, M.; Stahl, S.; Gannon, K.S.; Jacobs, T.G.; Buras, W.R.; Bymaster, F.P.; Zhang, W.; Spencer, K.A.; Feldman, P.D.; Meltzer, H.Y. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry, 2001, 158(1), 131-134. http://dx.doi.org/10.1176/appi.ajp.158.1.131
35. Thase, M.E.; Corya, S.A.; Osuntokun, O.; Case, M.; Henley, D.B.; Sanger, T.M.; Watson, S.B.; Dubé, S. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J. Clin. Psychiatry, 2007, 68(2), 224-236. http://dx.doi.org/10.4088/JCP.v68n0207
36. Shelton, R.C.; Williamson, D.J.; Corya, S.A.; Sanger, T.M.; Van Campen, L.E.; Case, M.; Briggs, S.D.; Tollefson, G.D. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J. Clin. Psychiatry, 2005, 66(10), 1289-1297. http://dx.doi.org/10.4088/JCP.v66n1012
37. Corya, S.A.; Williamson, D.; Sanger, T.M.; Briggs, S.D.; Case, M.; Tollefson, G. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress. Anxiety, 2006, 23(6), 364-372. http://dx.doi.org/10.1002/da.20130
38. Farooq, S.; Singh, S.P. Fixed dose-combination products in psychiatry: Systematic review and meta-analysis. J. Psychopharmacol., 2014, 29, 556-64.
39. Trivedi, M.H.; Thase, M.E.; Osuntokun, O.; Henley, D.B.; Case, M.; Watson, S.B.; Campbell, G.M.; Corya, S.A. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J. Clin. Psychiatry, 2009, 70(3), 387-396. http://dx.doi.org/10.4088/JCP.08m04064
40. Brunner, E.; Tohen, M.; Osuntokun, O.; Landry, J.; Thase, M.E. Efficacy and Safety of Olanzapine/Fluoxetine Combination vs Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology, 2014, 39(11), 2549-2559. http://dx.doi.org/10.1038/npp.2014.101
41. Bauer, M.; Pretorius, H.W.; Constant, E.L.; Earley, W.R.; Szamosi, J.; Brecher, M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J. Clin. Psychiatry, 2009, 70(4), 540-549. http://dx.doi.org/10.4088/JCP.08m04629
42. Bauer, M.; Demyttenaere, K.; El-Khalili, N.; Thase, M.E.; Papakostas, G.I.; Szamosi, J.; Earley, W.R.; Eriksson, H. Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment. Int. Clin. Psychopharmacol., 2014, 29(1), 16-25. http://dx.doi.org/10.1097/YIC.0000000000000011
43. Bauer, M.; Dell'osso, L.; Kasper, S.; Pitchot, W.; Dencker Vansvik, E.; Köhler, J.; Jørgensen, L.; Montgomery, S.A. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. J. Affect. Disord., 2013, 151(1), 209-219. http://dx.doi.org/10.1016/j.jad.2013.05.079
44. Thase, M.E.; Montgomery, S.; Papakostas, G.I.; Bauer, M.; Trivedi, M.H.; Svedsäter, H.; Locklear, J.C.; Gustafsson, U.; Datto, C.; Eriksson, H. Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy. Int. Clin. Psychopharmacol., 2013, 28(3), 113-120. http://dx.doi.org/10.1097/YIC.0b013e32835fb971
45. Rapaport, M.H.; Gharabawi, G.M.; Canuso, C.M.; Mahmoud, R.A.; Keller, M.B.; Bossie, C.A.; Turkoz, I.; Lasser, R.A.; Loescher, A.; Bouhours, P.; Dunbar, F.; Nemeroff, C.B. Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by doubleblind continuation. Neuropsychopharmacology, 2006, 31(11), 2505-2513. http://dx.doi.org/10.1038/sj.npp.1301113
46. Mahmoud, R.A.; Pandina, G.J.; Turkoz, I.; Kosik-Gonzalez, C.; Canuso, C.M.; Kujawa, M.J.; Gharabawi-Garibaldi, G.M. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann. Intern. Med., 2007, 147(9), 593-602. http://dx.doi.org/10.7326/0003-4819-147-9-200711060-00003
47. Keitner, G.I.; Garlow, S.J.; Ryan, C.E.; Ninan, P.T.; Solomon, D.A.; Nemeroff, C.B.; Keller, M.B. A randomized, placebocontrolled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J. Psychiatr. Res., 2009, 43(3), 205-214. http://dx.doi.org/10.1016/j.jpsychires.2008.05.003
48. Reeves, H.; Batra, S.; May, R.S.; Zhang, R.; Dahl, D.C.; Li, X. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J. Clin. Psychiatry, 2008, 69(8), 1228-1336. http://dx.doi.org/10.4088/JCP.v69n0805
49. Berman, R.M.; Fava, M.; Thase, M.E.; Trivedi, M.H.; Swanink, R.; McQuade, R.D.; Carson, W.H.; Adson, D.; Taylor, L.; Hazel, J.; Marcus, R.N. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr., 2009, 14(4), 197-206.
50. Berman, R.M.; Marcus, R.N.; Swanink, R.; McQuade, R.D.; Carson, W.H.; Corey-Lisle, P.K.; Khan, A. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry, 2007, 68(6), 843-853. http://dx.doi.org/10.4088/JCP.v68n0604
51. Marcus, R.N.; McQuade, R.D.; Carson, W.H.; Hennicken, D.; Fava, M.; Simon, J.S.; Trivedi, M.H.; Thase, M.E.; Berman, R.M. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol., 2008, 28(2), 156-165. http://dx.doi.org/10.1097/JCP.0b013 e31816774f9
52. Stewart, T.D.; Hatch, A.; Largay, K.; Sheehan, J.J.; Marler, S.V.; Berman, R.M.; Nelson, J.C. Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis. J. Affect. Disord., 2014, 162, 20-25. http://dx.doi.org/10.1016/j.jad.2014.03.017
53. Nelson, J.C.; Thase, M.E.; Bellocchio, E.E.; Rollin, L.M.; Eudicone, J.M.; McQuade, R.D.; Marcus, R.N.; Berman, R.M.; Baker, R.A. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. Int. Clin. Psychopharmacol., 2012, 27(3), 125-133. http://dx.doi.org/10.1097/YIC.0b013e3283502791
54. Fava, M.; Mischoulon, D.; Iosifescu, D.; Witte, J.; Pencina, M.; Flynn, M.; Harper, L.; Levy, M.; Rickels, K.; Pollack, M. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother. Psychosom., 2012, 81(2), 87-97. http://dx.doi.org/10.1159/000332050
55. Dunner, D.L.; Amsterdam, J.D.; Shelton, R.C.; Loebel, A.; Romano, S.J. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J. Clin. Psychiatry, 2007, 68(7), 1071-1077. http://dx.doi.org/10.4088/JCP.v68n0714
56. Papakostas, G.I.; Vitolo, O.V.; Ishak, W.W.; Rapaport, M.H.; Zajecka, J.M.; Kinrys, G.; Mischoulon, D.; Lipkin, S.H.; Hails, K.A.; Abrams, J.; Ward, S.G.; Meisner, A.; Schoenfeld, D.A.; Shelton, R.C.; Winokur, A.; Okasha, M.S.; Bari, M.A.; Fava, M. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. J. Clin. Psychiatry, 2012, 73(12), 1541-1547. http://dx.doi.org/10.4088/JCP.12m07670
57. Szegedi, A.; Zhao, J.; van Willigenburg, A.; Nations, K.R.; Mackle, M.; Panagides, J. Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. BMC Psychiatry, 2011, 11, 101. http://dx.doi.org/10.1186/1471-244X-11-101
58. Marston, H.M.; Martin, F.D.; Papp, M.; Gold, L.; Wong, E.H.; Shahid, M. Attenuation of chronic mild stress-induced 'anhedonia' by asenapine is not associated with a 'hedonic' profile in intracranial self-stimulation. J. Psychopharmacol., 2011, 25(10), 1388-1398. http://dx.doi.org/10.1177/0269881110376684
59. Kato, M.; Chang, C.M. Augmentation treatments with secondgeneration antipsychotics to antidepressants in treatment-resistant depression. CNS Drugs, 2013, 27 Suppl. 1, S11-19. http://dx.doi.org/10.1007/s40263-012-0029-7
60. Machado-Vieira, R.; Manji, H.K.; Zarate, C.A. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord., 2009, 11 Suppl. 2, 92-109. http://dx.doi.org/10.1111/j.1399-5618. 2009.00714.x
61. de Sousa, R.T.; Machado-Vieira, R.; Zarate, C.A.; Manji, H.K. Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder. Expert Opin. Ther. Targets, 2014, 1-17. http://dx.doi.org/10.1517/14728222.2014.940893
62. Bauer, M.; Dopfmer, S. Lithium augmentation in treatmentresistant depression: meta-analysis of placebo-controlled studies. J. Clin. Psychopharmacol., 1999, 19(5), 427-434. http://dx.doi.org/10.1097/00004714-199910000-00006
63. Nelson, J.C.; Baumann, P.; Delucchi, K.; Joffe, R.; Katona, C. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J. Affect. Disord., 2014, 168C, 269-275. http://dx.doi.org/10.1016/j.jad.2014.05.053
64. Hoencamp, E.; Haffmans, J.; Dijken, W.A.; Huijbrechts, I.P. Lithium augmentation of venlafaxine: an open-label trial. J. Clin. Psychopharmacol., 2000, 20(5), 538-543. http://dx.doi.org/10.1097/00004714-200010000-00008
65. Dallal, A.; Fontaine, R.; Ontiveros, A.; Elie, R. Lithium carbonate augmentation of desipramine in refractory depression. Can. J. Psychiatry, 1990, 35(7), 608-611.
66. Nierenberg, A.A.; Fava, M.; Trivedi, M.H.; Wisniewski, S.R.; Thase, M.E.; McGrath, P.J.; Alpert, J.E.; Warden, D.; Luther, J.F.; Niederehe, G.; Lebowitz, B.; Shores-Wilson, K.; Rush, A.J. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am. J. Psychiatry, 2006, 163(9), 1519-1530; quiz 1665.
67. Aprahamian, I.; de Sousa, R.T.; Valiengo, L.C.; Machado-Vieira, R.; Forlenza, O.V. Lithium safety and tolerability in mood disorders: a critical review. Rev. Psiq. Clin., 2014, 41(1), 9-14. http://dx.doi.org/10.1590/0101-60830000411914
68. Bauer, M.; Bschor, T.; Kunz, D.; Berghöfer, A.; Ströhle, A.; Müller-Oerlinghausen, B. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am. J. Psychiatry, 2000, 157(9), 1429-1435. http://dx.doi.org/10.1176/appi.ajp.157.9.1429
69. Wilkinson, D.; Holmes, C.; Woolford, J.; Stammers, S.; North, J. Prophylactic therapy with lithium in elderly patients with unipolar major depression. Int. J. Geriatr. Psychiatry, 2002, 17(7), 619-622. http://dx.doi.org/10.1002/gps.671
70. Cipriani, A.; Hawton, K.; Stockton, S.; Geddes, J.R. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ, 2013, 346, f3646. http://dx.doi.org/10.1136/bmj.f3646
71. Aronson, R.; Offman, H.J.; Joffe, R.T.; Naylor, C.D. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch. Gen. Psychiatry, 1996, 53(9), 842-848. http://dx.doi.org/10.1001/archpsyc.1996.01830090090013
72. Altshuler, L.L.; Bauer, M.; Frye, M.A.; Gitlin, M.J.; Mintz, J.; Szuba, M.P.; Leight, K.L.; Whybrow, P.C. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am. J. Psychiatry, 2001, 158(10), 1617-1622. http://dx.doi.org/10.1176/appi.ajp.158.10.1617
73. Cooper-Kazaz, R.; Lerer, B. Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int. J. Neuropsychopharmacol., 2008, 11(5), 685-699. http://dx.doi.org/10.1017/S1461145707008206
74. Garlow, S.J.; Dunlop, B.W.; Ninan, P.T.; Nemeroff, C.B. The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder. J. Psychiatr. Res., 2012, 46(11), 1406-1413. http://dx.doi.org/10.1016/j.jpsychires.2012.08.009
75. Bauer, M.; Hellweg, R.; Gräf, K.J.; Baumgartner, A. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology, 1998, 18(6), 444-455. http://dx.doi.org/10.1016/S0893-133X(97)00181-4
76. Pfeiffer, H.; Scherer, J.; Albus, M. High dose L-thyroxine in therapy refractory depression. Case analysis and catamnesis as quality control. Nervenarzt, 2004, 75(3), 242-248. http://dx.doi.org/10.1007/s00115-003-1550-1
77. Łojko, D.; Rybakowski, J.K. L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression. J. Affect. Disord., 2007, 103(1 3), 253-256. http://dx.doi.org/10.1016/j.jad.2007.01.016
78. Appelhof, B.C.; Brouwer, J.P.; van Dyck, R.; Fliers, E.; Hoogendijk, W.J.; Huyser, J.; Schene, A.H.; Tijssen, J.G.; Wiersinga, W.M. Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. J. Clin. Endocrinol. Metab., 2004, 89(12), 6271-6276. http://dx.doi.org/10.1210/jc.2004-1147
79. Patkar, A.A.; Masand, P.S.; Pae, C.U.; Peindl, K.; Hooper-Wood, C.; Mannelli, P.; Ciccone, P. A randomized, double-blind, placebocontrolled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatmentresistant depression. J. Clin. Psychopharmacol., 2006, 26(6), 653-656. http://dx.doi.org/10.1097/01.jcp.0000246212.03530.fd
80. Ravindran, A.V.; Kennedy, S.H.; O'Donovan, M.C.; Fallu, A.; Camacho, F.; Binder, C.E. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J. Clin. Psychiatry, 2008, 69(1), 87-94. http://dx.doi.org/10.4088/JCP.v69n0112
81. Goss, A.J.; Kaser, M.; Costafreda, S.G.; Sahakian, B.J.; Fu, C.H. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J. Clin. Psychiatry, 2013, 74(11), 1101-1107. http://dx.doi.org/10.4088/JCP.13r08560
82. Fava, M.; Thase, M.E.; DeBattista, C.; Doghramji, K.; Arora, S.; Hughes, R.J. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann. Clin. Psychiatry, 2007, 19(3), 153-159. http://dx.doi.org/10.1080/10401230701464858
83. Trivedi, M.H.; Cutler, A.J.; Richards, C.; Lasser, R.; Geibel, B.B.; Gao, J.; Sambunaris, A.; Patkar, A.A. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. J. Clin. Psychiatry, 2013, 74(8), 802-809. http://dx.doi.org/10.4088/JCP.13m08360
84. Abbasowa, L.; Kessing, L.V.; Vinberg, M. Psychostimulants in moderate to severe affective disorder: a systematic review of randomized controlled trials. Nord. J. Psychiatry, 2013, 67(6), 369-382. http://dx.doi.org/10.3109/08039488.2012.752035
85. Corrigan, M.H.; Denahan, A.Q.; Wright, C.E.; Ragual, R.J.; Evans, D.L. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress. Anxiety, 2000, 11(2), 58-65. http://dx.doi.org/10.1002/(SICI)1520-6394(2000)11:2<58::AIDDA2>3.0.CO;2-H
86. Lattanzi, L.; Dell'Osso, L.; Cassano, P.; Pini, S.; Rucci, P.; Houck, P.R.; Gemignani, A.; Battistini, G.; Bassi, A.; Abelli, M.; Cassano, G.B. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord., 2002, 4(5), 307-314. http://dx.doi.org/10.1034/j.1399-5618.2002.01171.x
87. Franco-Chaves, J.A.; Mateus, C.F.; Luckenbaugh, D.A.; Martinez, P.E.; Mallinger, A.G.; Zarate, C.A. Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study. J. Affect. Disord., 2013, 149(1 3), 319-325. http://dx.doi.org/10.1016/j.jad.2013.02.003
88. Rogóz, Z.; Skuza, G.; Daniel, W.A.; Wójcikowski, J.; Dudek, D.; Wróbel, A. Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. Pharmacol. Rep., 2007, 59(6), 778-784.
89. Stryjer, R.; Strous, R.D.; Shaked, G.; Bar, F.; Feldman, B.; Kotler, M.; Polak, L.; Rosenzcwaig, S.; Weizman, A. Amantadine as augmentation therapy in the management of treatment-resistant depression. Int. Clin. Psychopharmacol., 2003, 18(2), 93-96. http://dx.doi.org/10.1097/00004850-200303000-00005
90. Appelberg, B.G.; Syvälahti, E.K.; Koskinen, T.E.; Mehtonen, O.P.; Muhonen, T.T.; Naukkarinen, H.H. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J. Clin. Psychiatry, 2001, 62(6), 448-452. http://dx.doi.org/10.4088/JCP.v62n0608
91. Landén, M.; Björling, G.; Agren, H.; Fahlén, T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J. Clin. Psychiatry, 1998, 59(12), 664-668. http://dx.doi.org/10.4088/JCP.v59n1204
92. Serafini, G.; Pompili, M.; Innamorati, M.; Dwivedi, Y.; Brahmachari, G.; Girardi, P. Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression. Curr. Pharm. Des., 2013, 19(10), 1898-1922. http://dx.doi.org/10.2174/13816128113199990293
93. Niciu, M.J.; Ionescu, D.F.; Richards, E.M.; Zarate, C.A. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J. Neural. Transm., 2014, 121(8), 907-924. http://dx.doi.org/10.1007/s00702-013-1130-x
94. Maeng, S.; Zarate, C.A.; Du, J.; Schloesser, R.J.; McCammon, J.; Chen, G.; Manji, H.K. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy- 5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry, 2008, 63(4), 349-352. http://dx.doi.org/10.1016/j.biopsych.2007. 05.028
95. DiazGranados, N.; Ibrahim, L.A.; Brutsche, N.E.; Ameli, R.; Henter, I.D.; Luckenbaugh, D.A.; Machado-Vieira, R.; Zarate, C.A. Rapid resolution of suicidal ideation after a single infusion of an Nmethyl- D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J. Clin. Psychiatry, 2010, 71(12), 1605-1611. http://dx.doi.org/10.4088/JCP.09m05327blu
96. Sanacora, G.; Kendell, S.F.; Levin, Y.; Simen, A.A.; Fenton, L.R.; Coric, V.; Krystal, J.H. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol. Psychiatry, 2007, 61(6), 822-825. http://dx.doi.org/10.1016/j. biopsych.2006.08.037
97. Zarate, C.A.; Payne, J.L.; Quiroz, J.; Sporn, J.; Denicoff, K.K.; Luckenbaugh, D.; Charney, D.S.; Manji, H.K. An open-label trial of riluzole in patients with treatment-resistant major depression. Am. J. Psychiatry, 2004, 161(1), 171-174. http://dx.doi.org/10.1176/appi.ajp.161.1.171
98. Shin, I.J.; Son, S.U.; Park, H.; Kim, Y.; Park, S.H.; Swanberg, K.; Shin, J.Y.; Ha, S.K.; Cho, Y.; Bang, S.Y.; Lew, J.H.; Cho, S.H.; Maeng, S. Preclinical evidence of rapid-onset antidepressant-like effect in Radix Polygalae extract. PLoS One, 2014, 9(2), e88617. http://dx.doi.org/10.1371/journal.pone.0088617
99. Ballard, E.D.; Ionescu, D.F.; Vande Voort, J.L.; Niciu, M.J.; Richards, E.M.; Luckenbaugh, D.A.; Brutsché, N.E.; Ameli, R.; Furey, M.L.; Zarate, C.A. Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety. J. Psychiatr. Res., 2014, 58, 161-166. http://dx.doi.org/10.1016/j.jpsychires.2014.07.027
100. Zarate, C.A.; Singh, J.B.; Carlson, P.J.; Brutsche, N.E.; Ameli, R.; Luckenbaugh, D.A.; Charney, D.S.; Manji, H.K. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry, 2006, 63(8), 856-864. http://dx.doi.org/10.1001/archpsyc.63.8.856
101. Murrough, J.W.; Perez, A.M.; Pillemer, S.; Stern, J.; Parides, M.K.; aan het Rot, M.; Collins, K.A.; Mathew, S.J.; Charney, D.S.; Iosifescu, D.V. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol. Psychiatry, 2013, 74(4), 250-256. http://dx.doi.org/10.1016/j.biopsych.2012.06.022
102. Lapidus, K.A.; Levitch, C.F.; Perez, A.M.; Brallier, J.W.; Parides, M.K.; Soleimani, L.; Feder, A.; Iosifescu, D.V.; Charney, D.S.; Murrough, J.W. A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder. Biol. Psychiatry, 2014, 76, 970-6. http://dx.doi.org/10.1016/j.biopsych.2014.03.026
103. Bokor, G.; Anderson, P.D. Ketamine: An Update on Its Abuse. J. Pharm. Pract., 2014, 27, 582-6. http://dx.doi.org/10.1177/0897190014525754
104. Drevets, W.C.; Furey, M.L. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol. Psychiatry, 2010, 67(5), 432-438. http://dx.doi.org/10.1016/j.biopsych.2009.11.021
105. Khajavi, D.; Farokhnia, M.; Modabbernia, A.; Ashrafi, M.; Abbasi, S.H.; Tabrizi, M.; Akhondzadeh, S. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry, 2012, 73(11), 1428-1433. http://dx.doi.org/10.4088/JCP.12m07706
106. Ellis, J.S.; Zarate, C.A.; Luckenbaugh, D.A.; Furey, M.L. Antidepressant treatment history as a predictor of response to scopolamine: clinical implications. J. Affect. Disord., 2014, 162, 39-42. http://dx.doi.org/10.1016/j.jad.2014.03.010
107. Heresco-Levy, U.; Gelfin, G.; Bloch, B.; Levin, R.; Edelman, S.; Javitt, D.C.; Kremer, I. A randomized add-on trial of high-dose Dcycloserine for treatment-resistant depression. Int. J. Neuropsychopharmacol., 2013, 16(3), 501-506. http://dx.doi.org/10.1017/S1461145712000910
108. Papakostas, G.I.; Cassiello, C.F.; Iovieno, N. Folates and Sadenosylmethionine for major depressive disorder. Can. J. Psychiatry, 2012, 57(7), 406-413.
109. Bousman, C.A.; Potiriadis, M.; Everall, I.P.; Gunn, J.M. Methylenetetrahydrofolate reductase (MTHFR) genetic variation and major depressive disorder prognosis: A five-year prospective cohort study of primary care attendees. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2014, 165(1), 68-76. http://dx.doi.org/10.1002/ajmg.b.32209
110. Papakostas, G.I.; Mischoulon, D.; Shyu, I.; Alpert, J.E.; Fava, M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am. J. Psychiatry, 2010, 167(8), 942-948. http://dx.doi.org/10.1176/appi.ajp.2009.09081198
111. Papakostas, G.I.; Shelton, R.C.; Zajecka, J.M.; Etemad, B.; Rickels, K.; Clain, A.; Baer, L.; Dalton, E.D.; Sacco, G.R.; Schoenfeld, D.; Pencina, M.; Meisner, A.; Bottiglieri, T.; Nelson, E.; Mischoulon, D.; Alpert, J.E.; Barbee, J.G.; Zisook, S.; Fava, M. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am. J. Psychiatry, 2012, 169(12), 1267-1274. http://dx.doi.org/10.1176/appi.ajp.2012.11071114
112. Miller, K.K.; Perlis, R.H.; Papakostas, G.I.; Mischoulon, D.; Losifescu, D.V.; Brick, D.J.; Fava, M. Low-dose transdermal testosterone augmentation therapy improves depression severity in women. CNS Spectr., 2009, 14(12), 688-694.
113. Miller, A.H.; Maletic, V.; Raison, C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry, 2009, 65(9), 732-741. http://dx.doi.org/10.1016/j.biopsych.2008.11.029
114. Serafini, G.; Pompili, M.; Elena Seretti, M.; Stefani, H.; Palermo, M.; Coryell, W.; Girardi, P. The role of inflammatory cytokines in suicidal behavior: a systematic review. Eur. Neuropsychopharmacol., 2013, 23(12), 1672-1686. http://dx.doi.org/10.1016/j.euroneuro.2013.06.002
115. Vogelzangs, N.; Beekman, A.T.; van Reedt Dortland, A.K.; Schoevers, R.A.; Giltay, E.J.; de Jonge, P.; Penninx, B.W. Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users. Neuropsychopharmacology, 2014, 39(7), 1624-1634. http://dx.doi.org/10.1038/npp.2014.9
116. Na, K.S.; Lee, K.J.; Lee, J.S.; Cho, Y.S.; Jung, H.Y. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2014, 48, 79-85. http://dx.doi.org/10.1016/j.pnpbp.2013.09.006
117. Raison, C.L.; Rutherford, R.E.; Woolwine, B.J.; Shuo, C.; Schettler, P.; Drake, D.F.; Haroon, E.; Miller, A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry, 2013, 70(1), 31-41. http://dx.doi.org/10.1001/2013.jamapsychiatry.4
118. Trivedi, M.H.; Greer, T.L.; Church, T.S.; Carmody, T.J.; Grannemann, B.D.; Galper, D.I.; Dunn, A.L.; Earnest, C.P.; Sunderajan, P.; Henley, S.S.; Blair, S.N. Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison. J. Clin. Psychiatry, 2011, 72(5), 677-684. http://dx.doi.org/10.4088/JCP.10m06743
119. Rethorst, C.D.; Toups, M.S.; Greer, T.L.; Nakonezny, P.A.; Carmody, T.J.; Grannemann, B.D.; Huebinger, R.M.; Barber, R.C.; Trivedi, M.H. Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol. Psychiatry, 2013, 18(10), 1119-1124. http://dx.doi.org/10.1038/mp.2012.125
120. Lawlor, D.A.; Hopker, S.W. The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials. BMJ, 2001, 322(7289), 763-767. http://dx.doi.org/10.1136/bmj.322.7289.763
121. Silveira, H.; Moraes, H.; Oliveira, N.; Coutinho, E.S.; Laks, J.; Deslandes, A. Physical exercise and clinically depressed patients: a systematic review and meta-analysis. Neuropsychobiology, 2013, 67(2), 61-68. http://dx.doi.org/10.1159/000345160
122. Krogh, J.; Nordentoft, M.; Sterne, J.A.; Lawlor, D.A. The effect of exercise in clinically depressed adults: systematic review and metaanalysis of randomized controlled trials. J. Clin. Psychiatry, 2011, 72(4), 529-538. http://dx.doi.org/10.4088/JCP.08r04913blu
123. Group, U.E.R. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet, 2003, 361(9360), 799-808. http://dx.doi.org/10.1016/S0140-6736(03)12705-5
124. Ren, J.; Li, H.; Palaniyappan, L.; Liu, H.; Wang, J.; Li, C.; Rossini, P.M. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: a systematic review and meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2014, 51, 181-189. http://dx.doi.org/10.1016/j.pnpbp.2014.02.004
125. Xie, J.; Chen, J.; Wei, Q. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: a meta-analysis of stimulus parameter effects. Neurological research, 2013, 35(10), 1084-1091. http://dx.doi.org/10.1179/1743132813Y.0000000245
126. Moreines, J.L.; McClintock, S.M.; Holtzheimer, P.E. Neuropsychologic effects of neuromodulation techniques for treatmentresistant depression: a review. Brain Stimul, 2011, 4(1), 17-27. http://dx.doi.org/10.1016/j.brs.2010.01.005
127. Association, A.P. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. In: Arlington, VA; 2010.
128. Fitzgerald, P.B.; Hoy, K.E.; Herring, S.E.; Clinton, A.M.; Downey, G.; Daskalakis, Z.J. Pilot study of the clinical and cognitive effects of high-frequency magnetic seizure therapy in major depressive disorder. Depress. Anxiety, 2013, 30(2), 129-136. http://dx.doi.org/10.1002/da.22005
129. Fregni, F.; Pascual-Leone, A. Technology insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential of rTMS and tDCS. Nat. Clin. Pract. Neurol., 2007, 3(7), 383-393. http://dx.doi.org/10.1038/ncpneuro0530
130. Pascual-Leone, A.; Rubio, B.; Pallardo, F.; Catala, M.D. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet, 1996, 348(9022), 233-237. http://dx.doi.org/10.1016/S0140-6736(96)01219-6
131. Fitzgerald, P.B.; Benitez, J.; de Castella, A.; Daskalakis, Z.J.; Brown, T.L.; Kulkarni, J. A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression. Am. J. Psychiatry, 2006, 163(1), 88-94. http://dx.doi.org/10.1176/appi.ajp.163.1.88
132. O'Reardon, J.P.; Solvason, H.B.; Janicak, P.G.; Sampson, S.; Isenberg, K.E.; Nahas, Z.; McDonald, W.M.; Avery, D.; Fitzgerald, P.B.; Loo, C.; Demitrack, M.A.; George, M.S.; Sackeim, H.A. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol. Psychiatry, 2007, 62(11), 1208-1216. http://dx.doi.org/10.1016/j.biopsych.2007.01.018
133. George, M.S.; Lisanby, S.H.; Avery, D.; McDonald, W.M.; Durkalski, V.; Pavlicova, M.; Anderson, B.; Nahas, Z.; Bulow, P.; Zarkowski, P.; Holtzheimer, P.E., 3rd; Schwartz, T.; Sackeim, H.A. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch. Gen. Psychiatry, 2010, 67(5), 507-516. http://dx.doi.org/10.1001/archgenpsychiatry.2010.46
134. Lisanby, S.H.; Husain, M.M.; Rosenquist, P.B.; Maixner, D.; Gutierrez, R.; Krystal, A.; Gilmer, W.; Marangell, L.B.; Aaronson, S.; Daskalakis, Z.J.; Canterbury, R.; Richelson, E.; Sackeim, H.A.; George, M.S. Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology, 2009, 34(2), 522-534.
135. Lam, R.W.; Chan, P.; Wilkins-Ho, M.; Yatham, L.N. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and metaanalysis. Can. J. Psychiatry, 2008, 53(9), 621-631.
136. Gaynes, B.N.; Lloyd, S.W.; Lux, L.; Gartlehner, G.; Hansen, R.A.; Brode, S.; Jonas, D.E.; Swinson Evans, T.; Viswanathan, M.; Lohr, K.N. Repetitive transcranial magnetic stimulation for treatmentresistant depression: a systematic review and meta-analysis. J. clin. psychiatry, 2014, 75(5), 477-489. http://dx.doi.org/10.4088/JCP.13r08815
137. O'Reardon, J.P.; Cristancho, P.; Pilania, P.; Bapatla, K.B.; Chuai, S.; Peshek, A.D. Patients with a major depressive episode responding to treatment with repetitive transcranial magnetic stimulation (rTMS) are resistant to the effects of rapid tryptophan depletion. Depress. Anxiety, 2007, 24(8), 537-544. http://dx.doi.org/10.1002/da.20261
138. Berlim, M.T.; Van den Eynde, F.; Jeff D. Z . Clinically meaningful efficacy and acceptability of low-frequency repetitive transcranial magnetic stimulation (rTMS) for treating primary major depression: a meta-analysis of randomized, double-blind and shamcontrolled trials. Neuropsychopharmacology, 2013, 38(4), 543-551. http://dx.doi.org/10.1038/npp.2012.237
139. Rossi, S.; Hallett, M.; Rossini, P.M.; Pascual-Leone, A. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin. Neurophysiol, 2009, 120(12), 2008-2039. http://dx.doi.org/10.1016/j.clinph.2009.08.016
140. Xia, G.; Gajwani, P.; Muzina, D.J.; Kemp, D.E.; Gao, K.; Ganocy, S.J.; Calabrese, J.R. Treatment-emergent mania in unipolar and bipolar depression: focus on repetitive transcranial magnetic stimulation. Inter. J. Neuropsychopharmacol., 2008, 11(1), 119-130.
141. Connolly, K.R.; Helmer, A.; Cristancho, M.A.; Cristancho, P.; O'Reardon, J.P. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center. J. Clin. Psychiatry, 2012, 73(4), e567-573. http://dx.doi.org/10.4088/JCP.11m07413
142. Richieri, R.; Guedj, E.; Michel, P.; Loundou, A.; Auquier, P.; Lancon, C.; Boyer, L. Maintenance transcranial magnetic stimulation reduces depression relapse: A propensity-adjusted analysis. J. Affect. Disord., 2013, 151(1), 129-135. http://dx.doi.org/10.1016/j.jad.2013.05.062
143. Berlim, M.T.; Van den Eynde, F.; Tovar-Perdomo, S.; Chachamovich, E.; Zangen, A.; Turecki, G. Augmenting antidepressants with deep transcranial magnetic stimulation (DTMS) in treatment-resistant major depression. World J. Biol. Psychiatry, 2014, 15(7), 570-578. http://dx.doi.org/10.3109/15622975.2014.925141
144. Müller, H.H.; Kornhuber, J.; Maler, J.M.; Sperling, W. The effects of stimulation parameters on clinical outcomes in patients with vagus nerve stimulation implants with major depression. J. ECT, 2013, 29(3), e40-42. http://dx.doi.org/10.1097/YCT.0b013e318290f7ed
145. Aaronson, S.T.; Carpenter, L.L.; Conway, C.R.; Reimherr, F.W.; Lisanby, S.H.; Schwartz, T.L.; Moreno, F.A.; Dunner, D.L.; Lesem, M.D.; Thompson, P.M.; Husain, M.; Vine, C.J.; Banov, M.D.; Bernstein, L.P.; Lehman, R.B.; Brannon, G.E.; Keepers, G.A.; O'Reardon, J.P.; Rudolph, R.L.; Bunker, M. Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects. Brain Stimul., 2013, 6(4), 631-640. http://dx.doi.org/10.1016/j. brs.2012.09.013
146. Rush, A.J.; George, M.S.; Sackeim, H.A.; Marangell, L.B.; Husain, M.M.; Giller, C.; Nahas, Z.; Haines, S.; Simpson, R.K.; Goodman, R. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol. Psychiatry, 2000, 47(4), 276-286. http://dx.doi.org/10.1016/S0006-3223(99)00304-2
147. Schlaepfer, T.E.; Frick, C.; Zobel, A.; Maier, W.; Heuser, I.; Bajbouj, M.; O'Keane, V.; Corcoran, C.; Adolfsson, R.; Trimble, M.; Rau, H.; Hoff, H.J.; Padberg, F.; Müller-Siecheneder, F.; Audenaert, K.; Van den Abbeele, D.; Matthews, K.; Christmas, D.; Stanga, Z.; Hasdemir, M. Vagus nerve stimulation for depression: efficacy and safety in a European study. Psychol. Med., 2008, 38(5), 651-661. http://dx.doi.org/10.1017/S0033291707001924
148. Rush, A.J.; Marangell, L.B.; Sackeim, H.A.; George, M.S.; Brannan, S.K.; Davis, S.M.; Howland, R.; Kling, M.A.; Rittberg, B.R.; Burke, W.J.; Rapaport, M.H.; Zajecka, J.; Nierenberg, A.A.; Husain, M.M.; Ginsberg, D.; Cooke, R.G. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol. Psychiatry, 2005, 58(5), 347-354. http://dx.doi.org/10.1016/j.biopsych.2005.05.025
149. Brunoni, A.R.; Teng, C.T.; Correa, C.; Imamura, M.; Brasil-Neto, J.P.; Boechat, R.; Rosa, M.; Caramelli, P.; Cohen, R.; Del Porto, J.A.; Boggio, P.S.; Fregni, F. Neuromodulation approaches for the treatment of major depression: challenges and recommendations from a working group meeting. Arquivos de Neuropsiquiatria, 2010, 68(3), 433-451. http://dx.doi.org/10.1590/S0004-282X2010000300021
150. Cook, I.A.; Schrader, L.M.; Degiorgio, C.M.; Miller, P.R.; Maremont, E.R.; Leuchter, A.F. Trigeminal nerve stimulation in major depressive disorder: acute outcomes in an open pilot study. Epilepsy Behav., 2013, 28(2), 221-226.
151. Lipsman, N.; Sankar, T.; Downar, J.; Kennedy, S.H.; Lozano, A.M.; Giacobbe, P. Neuromodulation for treatment-refractory major depressive disorder. CMAJ, 2014, 186(1), 33-39.
152. Smith, D.F. Exploratory meta-analysis on deep brain stimulation in treatment-resistant depression. Acta. Neuropsychiatr., 2014, 26, 382-4. http://dx.doi.org/10.1017/neu.2014.22
153. Shiozawa, P.; Fregni, F.; Bensenor, I.M.; Lotufo, P.A.; Berlim, M.T.; Daskalakis, J.Z.; Cordeiro, Q.; Brunoni, A.R. Transcranial direct current stimulation for major depression: an updated systematic review and meta-analysis. Inter. J. Neuropsychopharmacol., 2014, 17, 1443-52.
154. Newton-Howes, G.; Tyrer, P.; Johnson, T.; Mulder, R.; Kool, S.; Dekker, J.; Schoevers, R. Influence of personality on the outcome of treatment in depression: systematic review and meta-analysis. J. Pers. Disord., 2014, 28(4), 577-593. http://dx.doi.org/10.1521/pedi_2013_27_070
155. Newton-Howes, G.; Tyrer, P.; Johnson, T. Personality disorder and the outcome of depression: meta-analysis of published studies. Br. J. Psychiatry, 2006, 188, 13-20. http://dx.doi.org/10.1192/bjp.188.1.13
156. Souery, D.; Oswald, P.; Massat, I.; Bailer, U.; Bollen, J.; Demyttenaere, K.; Kasper, S.; Lecrubier, Y.; Montgomery, S.; Serretti, A.; Zohar, J.; Mendlewicz, J.; Depression, G.F.T.S.O.R. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J. Clin. Psychiatry, 2007, 68(7), 1062-1070. http://dx.doi.org/10.4088/JCP.v68n0713
157. Rane, L.J.; Fekadu, A.; Wooderson, S.; Poon, L.; Markopoulou, K.; Cleare, A.J. Discrepancy between subjective and objective severity in treatment-resistant depression: prediction of treatment outcome. J. Psychiatr. Res., 2010, 44(15), 1082-1087. http://dx.doi.org/10.1016/j.jpsychires.2010.03.020
158. Pompili, M.; Venturini, P.; Palermo, M.; Stefani, H.; Seretti, M.E.; Lamis, D.A.; Serafini, G.; Amore, M.; Girardi, P. Mood disorders medications: predictors of nonadherence - review of the current literature. Expert. Rev. Neurother., 2013, 13(7), 809-825. http://dx.doi.org/10.1586/14737175.2013.811976
159. Takahashi, M.; Shirayama, Y.; Muneoka, K.; Suzuki, M.; Sato, K.; Hashimoto, K. Personality traits as risk factors for treatmentresistant depression. PLoS One, 2013, 8(5), e63756. http://dx.doi.org/10.1371/journal.pone.0063756
160. Seemüller, F.; Meier, S.; Obermeier, M.; Musil, R.; Bauer, M.; Adli, M.; Kronmüller, K.; Holsboer, F.; Brieger, P.; Laux, G.; Bender, W.; Heuser, I.; Zeiler, J.; Gaebel, W.; Riedel, M.; Falkai, P.; Möller, H.J. Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors. Eur. Arch. Psychiatry Clin. Neurosci., 2014, 264(7), 567-575. http://dx.doi.org/10.1007/s00406-014-0495-7
161. McGirr, A.; Van den Eynde, F.; Chachamovich, E.; Fleck, M.P.; Berlim, M.T. Personality dimensions and deep repetitive transcranial magnetic stimulation (DTMS) for treatment-resistant depression: a pilot trial on five-factor prediction of antidepressant response. Neurosci. Lett., 2014, 563, 144-148. http://dx.doi.org/10.1016/j.neulet.2014.01.037
162. Keitner, G.I.; Mansfield, A.K. Management of treatment-resistant depression. Psychiatr. Clin. North Am., 2012, 35(1), 249-265. http://dx.doi.org/10.1016/j.psc.2011.11.004
163. Thase, M.E.; Friedman, E.S.; Biggs, M.M.; Wisniewski, S.R.; Trivedi, M.H.; Luther, J.F.; Fava, M.; Nierenberg, A.A.; McGrath, P.J.; Warden, D.; Niederehe, G.; Hollon, S.D.; Rush, A.J. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am. J. Psychiatry, 2007, 164(5), 739-752. http://dx.doi.org/10.1176/ajp.2007.164.5.739
164. Wiles, N.; Thomas, L.; Abel, A.; Ridgway, N.; Turner, N.; Campbell, J.; Garland, A.; Hollinghurst, S.; Jerrom, B.; Kessler, D.; Kuyken, W.; Morrison, J.; Turner, K.; Williams, C.; Peters, T.; Lewis, G. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet, 2013, 381(9864), 375-384. http://dx.doi.org/10.1016/S0140-6736(12)61552-9
165. Hofmann, S.G.; Asnaani, A.; Vonk, I.J.; Sawyer, A.T.; Fang, A. The Efficacy of Cognitive Behavioral Therapy: A Review of Metaanalyses. Cognit. Ther. Res., 2012, 36(5), 427-440. http://dx.doi.org/10.1007/s10608-012-9476-1
166. Abbass, A.; Town, J.; Driessen, E. The efficacy of short-term psychodynamic psychotherapy for depressive disorders with comorbid personality disorder. Psychiatry, 2011, 74(1), 58-71. http://dx.doi.org/10.1521/psyc.2011.74.1.58
167. Leichsenring, F.; Rabung, S. Long-term psychodynamic psychotherapy in complex mental disorders: update of a meta-analysis. Br. J. Psychiatry, 2011, 199(1), 15-22. http://dx.doi.org/10.1192/bjp.bp.110.082776
168. Fagiolini, A.; Kupfer, D.J. Is treatment-resistant depression a unique subtype of depression? Biol. Psychiatry, 2003, 53(8), 640-648. http://dx.doi.org/10.1016/S0006-3223(02)01670-0
169. Macneil, C.A.; Hasty, M.K.; Conus, P.; Berk, M. Is diagnosis enough to guide interventions in mental health? Using case formulation in clinical practice. BMC Med., 2012, 10, 111. http://dx.doi.org/10.1186/1741-7015-10-111